Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria - Analysis from the @-Registry

BJU International

Volumn 108, Issue 8 B, 2011, Pages

  Ganzer, Roman ^a   Robertson, Cary N ^d   Ward, John F ^e   Brown, Stephen C W ^f   Conti, Giario N ^g   Murat, Francois J ^h   Pasticier, Gilles ⁱ   Rebillard, Xavier ^j   Thuroff, Stefan ^b   Wieland, Wolf F ^a   Blana, Andreas ^c  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Harlaching Hospital   (Germany)

^c Fuerth Hospital   (Germany)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f STEPPING HILL HOSPITAL   (United Kingdom)

^g SANT ANNA HOSPITAL   (Italy)

^h EDOUARD HERRIOT HOSPITAL   (France)

ⁱ HÔPITAL PELLEGRIN   (France)

^j Department of Urology   (France)

more..

Author keywords

biochemical failure; follow up; high intensity focused ultrasound; nadir; prostate cancer; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BIOCHEMISTRY; CANCER REGISTRY; CLINICAL PRACTICE; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; GLEASON SCORE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TRANSURETHRAL RESECTION; TREATMENT FAILURE; TREATMENT OUTCOME;

DISEASE-FREE SURVIVAL; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGISTRIES; RETROSPECTIVE STUDIES; TREATMENT FAILURE; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 80054051297     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10091.x     Document Type: Article

References (20)

1. Ganzer R, Rogenhofer S, Walter B, et al,. PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer. Eur Urol 2008; 53: 547-53
2. Uchida T, Illing RO, Cathcart PJ, Emberton M,. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int 2006; 98: 537-9 (Pubitemid 44185871)
3. Gelet A, Chapelon JY, Bouvier R, et al,. Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. Eur Urol 1996; 29: 174-83 (Pubitemid 26059421)
4. Gelet A, Chapelon JY, Bouvier R, Pangaud C, Lasne Y,. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results. J Urol 1999; 161: 156-62 (Pubitemid 29422311)
5. Gelet A, Chapelon JY, Bouvier R, et al,. Transrectal high-intensity focused ultrasound: minimally invasive therapy of localized prostate cancer. J Endourol 2000; 14: 519-28 (Pubitemid 30655584)
6. ASTRO. Consensus Statement. Guidelines for PDSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: 1035-41
7. Blana A, Rogenhofer S, Ganzer R, et al,. Eight years' experience with high-intensity focused ultrasonography for treatment of localized prostate cancer. Urology 2008; 72: 1329-33
8. Blana A, Brown SC, Chaussy C, et al,. High intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int 2009; 104: 1058-62
9. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH,. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003; 21: 2163-72 (Pubitemid 46606365)
10. Blana A, Murat FJ, Walter B, et al,. First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol 2008; 53: 1194-201
11. Tsakiris P, Thüroff S, de la Rosette J, Chaussy C,. Transrectal high-intensity focused ultrasound devices: a critical appraisal of the available evidence. J Endourol 2008; 22: 221-9 (Pubitemid 351305937)
12. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H,. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000; 164: 1-5
13. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT,. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167: 528-34 (Pubitemid 34074521)
14. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC,. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169: 517-23 (Pubitemid 36132976)
15. Rosser CJ, Chichakli R, Levy LB, Kuban DA, Smith LG, Pisters LL,. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with external beam radiation. J Urol 2002; 168: 536-41 (Pubitemid 34793289)
16. Kuban DA, Thames HD, Levy LB, et al,. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2003; 57: 915-28 (Pubitemid 37324109)
17. Poissonnier L, Chapelon JY, Rouviere O, et al,. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007; 51: 381-7 (Pubitemid 44937777)
18. Neumayr A, Thueroff S, Nanieva R, Steil W, Leeser C, Chaussy C,. PSA nadir development after local therapy by robotic high intensity focused ultrasound therapy (RHIFU) of T1-2 prostate cancer. J Endourol 2009; 23 (Suppl. 1): A175
19. Vallancien G, Prapotnich D, Cathelineau X, Baumert H, Rozet F,. Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol 2004; 171 (6 Pt 1): 2265-7 (Pubitemid 38625448)
20. Jones JS, Rewcastle JC, Donnelly BJ, Lugnani FM, Pisters LL, Katz AE,. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. J Urol 2008; 180: 554-8